Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:CALT NASDAQ:GOSS NASDAQ:MRUS NASDAQ:OGI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$57.51$60.01$11.40▼$72.36$1.67B0.72541,386 shs827,833 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AGOSSGossamer Bio$0.17$0.28$0.14▼$3.87$39.43M215.34 million shs23.16 million shsMRUSMerus$90.00-7.1%$93.01$37.92▼$97.14$6.83B1.061.51 million shs2.73 million shsOGIOrganigram Global$0.96$1.22$0.95▼$2.24$135.80M1.43584,449 shs708,382 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio0.00%+2.57%-4.28%-7.79%+145.87%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%0.00%GOSSGossamer Bio0.00%+3.77%-21.97%-60.23%-86.98%MRUSMerus0.00%0.00%0.00%0.00%+71.14%OGIOrganigram Global0.00%-8.99%-9.84%-29.07%-26.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$57.51$60.01$11.40▼$72.36$1.67B0.72541,386 shs827,833 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AGOSSGossamer Bio$0.17$0.28$0.14▼$3.87$39.43M215.34 million shs23.16 million shsMRUSMerus$90.00-7.1%$93.01$37.92▼$97.14$6.83B1.061.51 million shs2.73 million shsOGIOrganigram Global$0.96$1.22$0.95▼$2.24$135.80M1.43584,449 shs708,382 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio0.00%+2.57%-4.28%-7.79%+145.87%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%0.00%GOSSGossamer Bio0.00%+3.77%-21.97%-60.23%-86.98%MRUSMerus0.00%0.00%0.00%0.00%+71.14%OGIOrganigram Global0.00%-8.99%-9.84%-29.07%-26.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.69Moderate Buy$81.8242.27% UpsideCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AGOSSGossamer Bio 2.20Hold$5.002,876.19% UpsideMRUSMerus 2.00Hold$95.936.59% UpsideOGIOrganigram Global 2.33HoldN/AN/ACurrent Analyst Ratings BreakdownLatest MRUS, ANAB, GOSS, OGI, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026ANABAnaptysBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$95.006/9/2026OGIOrganigram Global Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/2/2026ANABAnaptysBio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/26/2026GOSSGossamer Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/19/2026GOSSGossamer Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026ANABAnaptysBio Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$90.005/13/2026ANABAnaptysBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026ANABAnaptysBio UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $76.005/13/2026ANABAnaptysBio BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$63.00 ➝ $75.005/4/2026ANABAnaptysBio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/4/2026ANABAnaptysBio Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$95.00 ➝ $93.00(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$234.60M7.13N/AN/A$1.34 per share42.92CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74GOSSGossamer Bio$48.47M0.81N/AN/A($0.53) per share-0.32MRUSMerus$36.13M188.94N/AN/A$9.46 per share9.51OGIOrganigram Global$185.07M0.73N/AN/A$1.86 per share0.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$13.23M-$1.08N/A17.70N/A-11.53%-1,101.24%-7.75%8/5/2026 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AGOSSGossamer Bio-$170.37M-$0.79N/AN/AN/A-324.82%N/A-96.10%8/4/2026 (Estimated)MRUSMerus-$215.33M-$5.30N/AN/AN/A-673.31%-52.99%-44.61%N/AOGIOrganigram Global-$17.70M-$0.13N/A24.12N/A-9.22%-13.41%-9.09%8/12/2026 (Estimated)Latest MRUS, ANAB, GOSS, OGI, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026GOSSGossamer Bio-$0.17-$0.20-$0.03-$0.20$4.67 million$16.96 million5/12/2026Q1 2026ANABAnaptysBio-$0.6436-$1.84-$1.1965-$1.84$18.86 million$25.56 million5/12/2026Q2 2026OGIOrganigram Global-$0.01-$0.01N/A-$0.01$50.56 million$42.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A7.587.58CALTCalliditas Therapeutics AB (publ)9.442.692.59GOSSGossamer BioN/A2.202.20MRUSMerusN/A7.977.97OGIOrganigram GlobalN/A2.821.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ACALTCalliditas Therapeutics AB (publ)2.83%GOSSGossamer Bio81.23%MRUSMerus96.14%OGIOrganigram Global34.63%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%CALTCalliditas Therapeutics AB (publ)2.20%GOSSGossamer Bio3.74%MRUSMerus3.70%OGIOrganigram Global0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.10 million19.35 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionNo DataGOSSGossamer Bio180234.70 million225.92 millionOptionableMRUSMerus3775.85 million73.04 millionOptionableOGIOrganigram Global1,139140.77 million140.64 millionOptionableMRUS, ANAB, GOSS, OGI, and CALT HeadlinesRecent News About These CompaniesOrganigram Global Inc (OGI) Raises 2026 Guidance on Sanity AcquisitionMay 31, 2026 | insidermonkey.comBuy this cannabis stock for a double, analyst saysMay 18, 2026 | cantechletter.comCOrganigram Global Inc (OGI) Q2 2026 Earnings Call Highlights: Navigating Challenges and Seizing ...May 13, 2026 | finance.yahoo.comTranscript: OrganiGram Holdings Q2 2026 Earnings Conference CallMay 13, 2026 | uk.finance.yahoo.comOrganiGram Holdings Reports Q2 2026 Results: Full Earnings Call TranscriptMay 13, 2026 | uk.finance.yahoo.comOrganigram Says Vape Weakness Pressures MarginsMay 12, 2026 | benzinga.comOrganiGram (OGI) Reports Q2 Loss, Misses Revenue EstimatesMay 12, 2026 | zacks.comOrganigram Global Files Q2 2026 Results as Sanity Group Deal Extends European Cannabis ReachMay 12, 2026 | tipranks.comOrganigram Reports Second Quarter Fiscal 2026 ResultsMay 12, 2026 | financialpost.comFOrganigram global Q2 earnings previewMay 11, 2026 | msn.comOrganigram Global Sets May 12 Date to Report Q2 2026 ResultsMay 6, 2026 | tipranks.comOrganigram to Report Second Quarter Fiscal 2026 Results on May 12th, 2026May 6, 2026 | financialpost.comFBritish American Tobacco buying at Organigram Global (OGI)May 1, 2026 | theglobeandmail.comOrganigram Global (OGI) Completes EUR 107.3 Million Acquisition of Sanity GroupApril 17, 2026 | finance.yahoo.comOrganigram Global (OGI) Completes EUR 107.3 Million Acquisition of Sanity GroupApril 17, 2026 | insidermonkey.comOrganigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit FacilitiesApril 15, 2026 | financialpost.comFOrganigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit FacilitiesApril 15, 2026 | businesswire.comWeekly Roundup on the Cannabis Sector & Psychedelic SectorApril 6, 2026 | finance.yahoo.comIs Organigram Global Inc. (OGI) Among the 11 Best Marijuana Stocks to Buy Right Now?April 1, 2026 | finance.yahoo.comIs Organigram Global Inc. (OGI) Among the 11 Best Marijuana Stocks to Buy Right Now?April 1, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026AI Server Earnings: Wall Street Sees One Clear StandoutBy Leo Miller | June 5, 2026IREN Is Flipping the Switch from Bitcoin to AIBy Jeffrey Neal Johnson | May 28, 2026Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for InvestorsBy Chris Markoch | June 2, 2026Palantir and Dell Build an AI OS for the ParanoidBy Chris Markoch | May 24, 2026MRUS, ANAB, GOSS, OGI, and CALT Company DescriptionsAnaptysBio NASDAQ:ANAB$57.51 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$57.54 +0.02 (+0.04%) As of 06/18/2026 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 06/18/2026Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Gossamer Bio NASDAQ:GOSS$0.17 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.18 +0.01 (+4.17%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Merus NASDAQ:MRUSMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Organigram Global NASDAQ:OGI$0.96 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.96 +0.00 (+0.03%) As of 06/18/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
